Precisio Biotix Therapeutics has entered a collaboration with Mayo Clinic, which will include co-development of novel precision antibacterials targeting indications prone to antimicrobial-resistant (AMR) infections.
 
Precisio creates lower cost novel precision biological antibacterials with a focus on lung and skin infections. The Company’s key assets include: LysiThru, the Company’s high throughput screening, engineering, and AI system for creating best- or first-in-class novel lysins (engineered precision enzymes that rapidly break targeted bacterial cell walls without causing resistance); a pipeline of lysin and phage products that will be able to address multiple problematic bacterial diseases, including AMR infections; and a strong scientific team to address the global need for novel medicines to fight AMR infections. 
 
Mayo Clinic has assets and know-how that complement Precisio’s lysins.
 
Dr. Assaf Raz, VP of R&D, stated: “We are delighted to work with Mayo Clinic. We see this collaboration as an opportunity for validation of our technology.  We believe that when combined with Mayo Clinic’s expertise, our precision biological antibacterials will be even more effective. Together we will be addressing some of the largest bacterial disease problems, particularly antibiotic resistance.”
 
Dr. Raymond Schuch, VP, Director of US Operations, added: “Antibiotic resistance is one of the world’s great health challenges. And this collaboration may result in patients having faster access to novel therapeutics.”
 
Mayo Clinic has a financial interest in the technology and will use any revenue it receives to support its patient care, education and research.